제약 환경 모니터링 시스템 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the pharmaceutical environmental monitoring system market size was valued at USD 1.48 billion in 2025 and is estimated to grow from USD 1.62 billion in 2026 to reach USD 2.58 billion by 2031, at a CAGR of 9.78% during the forecast period (2026-2031).

This report is Segmented by Offering (Hardware, Software & Services), Monitoring Type (Non-Viable Air Particle Monitoring, and More), Application (Aseptic Fill-Finish and Sterile Injectables, and More), End User (Pharmaceutical and Biotechnology Manufacturers, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Pharmaceutical Environmental Monitoring System Market Trends and Insights

Annex 1-Driven Shift to Continuous Monitoring in Grade A/B

Harmonization through PIC/S has extended these expectations across a large set of inspection authorities, which reduces ambiguity for global manufacturers that operate common platforms across regions. Inspectors now look for evidence that cleanrooms meet classification at rest and maintain real-time process control in operation supported by airflow visualization and robust trending. Legacy plants are prioritizing risk assessments, particle transport loss evaluations, and alarm integration into SCADA or BMS so that excursions tie directly to documented corrective and preventive actions.

Data-Integrity and 21 CFR Part 11 Validation Requirements

Persistent enforcement of 21 CFR Part 11 has raised the compliance bar for environmental monitoring systems with secure, immutable audit trails and role-based access across users and devices. Environmental data, alarm acknowledgments, threshold changes, and user actions are expected to be captured with full metadata and maintained in validated systems that support periodic review. The regulatory posture also covers compounding environments in the United States where environmental monitoring programs and data integrity procedures are integral to inspection readiness. Vendors are responding with cloud-capable platforms that meet audit trail, encryption, and authentication expectations while easing patching and backup overhead for quality and IT teams. The underlying aim in the pharmaceutical environmental monitoring system market is to maintain trustworthy, reviewable records that stand during audits and support rapid deviation investigation without manual data stitching.

High Upfront Cost and Validation Burden

Capital and validation workloads weigh most on smaller organizations and contract manufacturers that must qualify hardware, software, and alarm logic without disrupting production. Qualification steps across IQ, OQ, and PQ, along with calibration and documentation, extend timelines and add service costs that are difficult to absorb mid-campaign. Higher performance viable monitoring technologies promise faster decisions, yet they require careful method validation and change control before replacing culture-based routines. Project teams also face room closures to install fixed sampling points and integrate sensor networks with SCADA or BMS, which can compress qualification windows and create scheduling pressure. The pharmaceutical environmental monitoring system market contends with these hurdles by offering pre-validated packages and cloud-managed platforms that reduce server costs and facilitate updates within controlled procedures.

Other drivers and restraints analyzed in the detailed report include:

1. Expanding Aseptic Capacity in Biologics and CGT
2. Digitalization of EMS (Cloud/SCADA, Remote Alarming)
3. Brownfield Integration with Legacy BMS/IT

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Hardware captured 62.70% of the pharmaceutical environmental monitoring system market share in 2025 as airborne particle counters, viable samplers, and environmental sensors remain the core sensing layer in compliant cleanrooms. Fixed and remote particle counters continue to replace portable-only routines in aseptic operations, as sites pursue continuous monitoring with validated alert and action thresholds. Microbial air samplers and real-time viable counters are drawing interest where faster detection supports on-shift root cause analysis and better excursion response. Environmental sensors for temperature, humidity, airflow, and differential pressure remain essential in every suite, and they are increasingly tied into centralized platforms. At the same time, software platforms that manage alarms, audit trails, and reporting across plants are gaining adoption as teams standardize across global portfolios.

Software & Services is the fastest-growing component, and the pharmaceutical environmental monitoring system market size for this segment is projected to expand at 7.18% CAGR through 2031 as cloud-native architectures reduce server maintenance while meeting Part 11 expectations. Vendors are delivering validated audit trails, encryption, and role-based access in subscription models that ease updates without full requalification. Integration with SCADA and BMS lets teams connect environmental trends to process and equipment signals, which improves deviation investigations and energy control. In the pharmaceutical environmental monitoring system market, this shift is strongest among multi-site enterprises that want unified configurations across aseptic sites while preserving local workflows.

Non-viable Air Particle Monitoring held 41.13% in 2025 as the baseline classification and control tool for ISO and GMP compliance across Grades A through D. Annex 1 requires continuous monitoring during critical Grade A operations, and this standard is increasing deployments of fixed and remote counters linked to validated historians. Remote particle counters help sites avoid the labor and timing limits of portable-only routines and enable real-time responses to excursions during filling. The pharmaceutical environmental monitoring system market continues to rely on non-viable trends to indicate process instability that can precede bioburden movement, which makes continuous sampling essential for critical steps.

Viable Environmental Monitoring is the fastest-growing type with an 11.62% CAGR to 2031, driven by rapid microbiological methods that deliver actionable signals closer to real time. Laser-induced fluorescence viable counters, ATP bioluminescence, and other rapid approaches reduce time-to-result and support earlier intervention and better release decisions when paired with confirmatory culture. Case studies in sterile facilities show that integrated ID strategies and rapid detection shorten investigations without displacing compendial requirements Strategic investment by leading QC players underscores confidence in continuous viable monitoring as a complement to established microbiology. The pharmaceutical environmental monitoring system market therefore balances classical plate-based tools with rapid instruments that close information gaps during aseptic production.

Geography Analysis

North America retained 42.80% of the pharmaceutical environmental monitoring system market share in 2025 supported by concentrated biologics innovation, significant aseptic capacity, and strong Part 11 enforcement that anchors validated monitoring adoption. New U.S. projects in advanced therapies sustain demand for continuous non-viable and viable monitoring along with integrated alarm management that ties excursions to batch records. Canada and Mexico add incremental capacity with modernization in selected hubs, while U.S. compounding environments continue to formalize environmental monitoring under updated standards.

Europe remains a core pillar as Annex 1 enforcement catalyzes upgrades to continuous monitoring and harmonized contamination control strategies. Multinational manufacturers are aligning architectures across Germany, the United Kingdom, France, Italy, and Spain, which supports vendors able to provide consistent validation packages and field service. The pharmaceutical environmental monitoring system market in Europe also benefits from ongoing biologics investments and adoption of rapid viable technologies that reduce investigation delays without displacing compendial methods. Brownfield integration projects remain significant as plants update legacy controls and alarm logic to meet modern data integrity and continuous monitoring expectations.

Asia-Pacific is the fastest-growing region with a 13.13% CAGR through 2031 as greenfield aseptic capacity in China, India, and South Korea embeds continuous monitoring into project designs from day one. India's push into biosimilars and regulated-market submissions and China's drive for self-sufficiency in biologics are expanding the installed base that depends on validated, Annex 1-aligned monitoring. The pharmaceutical environmental monitoring system market size in the region reflects new facilities that prefer standardized, multi-site compatible platforms which ease training and validation as networks scale. Australia and Japan contribute with high-compliance deployments and cloud-forward monitoring across distributed networks, supported by vendors with proven Part 11 capabilities.

1. Beckman Coulter Life Sciences (MET ONE)
2. bioMerieux (Air IDEAL microbial air sampling)
3. Charles River
4. Climet Instruments Company
5. Dickson (incl. Oceasoft)
6. Ellab (incl. Hanwell Monitoring)
7. Kanomax
8. Lighthouse Worldwide Solutions
9. Merck KGaA (MAS-100 air sampling)
10. Met One Instruments (Acoem)
11. PAMAS Partikelmess
12. Particle Measuring Systems (Spectris)
13. Pharmagraph
14. Rees Scientific
15. RION
16. Rotronic / Process Sensing Technologies (PST)
17. SensoScientific
18. Setra Systems
19. TSI Incorporated
20. Vaisala
21. XiltriX International

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Annex 1-Driven Shift to Continuous Monitoring in Grade A/B
  • 4.2.2 Data-Integrity and 21 CFR Part 11 Validation Requirements
  • 4.2.3 Expanding Aseptic Capacity in Biologics and CGT
  • 4.2.4 Digitalization of EMS (Cloud/SCADA, Remote Alarming)
  • 4.2.5 USP <797> 2023 Enforcement in U.S. Compounding
  • 4.2.6 Energy Optimization Needs Driving Sensor-Led Control
• 4.3 Market Restraints
  • 4.3.1 High Upfront Cost and Validation Burden
  • 4.3.2 Brownfield Integration with Legacy BMS/IT
  • 4.3.3 Slow Acceptance of Rapid Viable Monitoring
  • 4.3.4 Cybersecurity and Cloud Policies Limiting Adoption
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Offering
  • 5.1.1 Hardware
    • 5.1.1.1 Airborne Particle Counters (portable, remote, handheld)
    • 5.1.1.2 Microbial Air Samplers (active, passive, rapid methods)
    • 5.1.1.3 Environmental Sensors (temperature, RH, DP, airflow, CO2)
    • 5.1.1.4 Data Loggers & Transmitters
    • 5.1.1.5 Controllers/IO/PLC & SCADA nodes
    • 5.1.1.6 Others
  • 5.1.2 Software & Services
• 5.2 By Monitoring Type
  • 5.2.1 Non-viable Air Particle Monitoring
  • 5.2.2 Viable Environmental Monitoring
  • 5.2.3 Environmental Parameters Monitoring (T/RH/DP/airflow/CO2)
  • 5.2.4 Utilities & Water Systems Monitoring (WFI/PW, compressed gases)
• 5.3 By Application
  • 5.3.1 Aseptic Fill-Finish and Sterile Injectables
  • 5.3.2 Biologics & Cell/Gene Therapy Suites
  • 5.3.3 Oral Solid Dose & Non-Sterile Manufacturing
  • 5.3.4 QC Microbiology Labs & Cleanroom Support
  • 5.3.5 Warehousing, Cold Rooms, and Distribution
  • 5.3.6 Others
• 5.4 By End User
  • 5.4.1 Pharmaceutical and Biotechnology Manufacturers
  • 5.4.2 CDMOs/CMOs
  • 5.4.3 Hospital Compounding Pharmacies
  • 5.4.4 Others
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 Beckman Coulter Life Sciences (MET ONE)
  • 6.3.2 bioMerieux (Air IDEAL microbial air sampling)
  • 6.3.3 Charles River Laboratories
  • 6.3.4 Climet Instruments Company
  • 6.3.5 Dickson (incl. Oceasoft)
  • 6.3.6 Ellab (incl. Hanwell Monitoring)
  • 6.3.7 Kanomax
  • 6.3.8 Lighthouse Worldwide Solutions
  • 6.3.9 Merck KGaA (MAS-100 air sampling)
  • 6.3.10 Met One Instruments (Acoem)
  • 6.3.11 PAMAS Partikelmess
  • 6.3.12 Particle Measuring Systems (Spectris)
  • 6.3.13 Pharmagraph
  • 6.3.14 Rees Scientific
  • 6.3.15 RION Co., Ltd.
  • 6.3.16 Rotronic / Process Sensing Technologies (PST)
  • 6.3.17 SensoScientific
  • 6.3.18 Setra Systems
  • 6.3.19 TSI Incorporated
  • 6.3.20 Vaisala
  • 6.3.21 XiltriX International

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment